HUP0302732A2 - Érproliferációt gátló gyógyszerészeti készítmények, és eljárás azok alkalmazására - Google Patents

Érproliferációt gátló gyógyszerészeti készítmények, és eljárás azok alkalmazására

Info

Publication number
HUP0302732A2
HUP0302732A2 HU0302732A HUP0302732A HUP0302732A2 HU P0302732 A2 HUP0302732 A2 HU P0302732A2 HU 0302732 A HU0302732 A HU 0302732A HU P0302732 A HUP0302732 A HU P0302732A HU P0302732 A2 HUP0302732 A2 HU P0302732A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
vascular proliferation
inhibit vascular
patient
proliferation
Prior art date
Application number
HU0302732A
Other languages
English (en)
Inventor
Guido Bocci
Romano Danesi
Mario Deltacca
Michael Dewitt Culler
Original Assignee
Société de Conseil de Recherches et d'Applications Scientifiques, S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Société de Conseil de Recherches et d'Applications Scientifiques, S.A.S. filed Critical Société de Conseil de Recherches et d'Applications Scientifiques, S.A.S.
Publication of HUP0302732A2 publication Critical patent/HUP0302732A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

A jelen találmány tárgyát egy olyan eljárás képezi, amely arraszolgál, hogy egy arra rászoruló betegben az érproliferációt kezelik.Ezen eljárás során az említett beteget egy olyan vegyületnek aterápiásan hatékony mennyiségével kezelik, amely vegyület az 1-estípusú szomatosztatinreceptor agonistája. Ó
HU0302732A 2001-01-12 2002-01-14 Érproliferációt gátló gyógyszerészeti készítmények, és eljárás azok alkalmazására HUP0302732A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26143901P 2001-01-12 2001-01-12
US27529401P 2001-03-13 2001-03-13
PCT/US2002/001125 WO2002064160A2 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof

Publications (1)

Publication Number Publication Date
HUP0302732A2 true HUP0302732A2 (hu) 2003-12-29

Family

ID=26948607

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302732A HUP0302732A2 (hu) 2001-01-12 2002-01-14 Érproliferációt gátló gyógyszerészeti készítmények, és eljárás azok alkalmazására

Country Status (15)

Country Link
US (1) US7084117B2 (hu)
EP (1) EP1409007A2 (hu)
JP (1) JP4099065B2 (hu)
KR (1) KR20030068585A (hu)
CN (1) CN1531441A (hu)
AU (1) AU2002243552C1 (hu)
CA (1) CA2433785C (hu)
CZ (1) CZ20031695A3 (hu)
HU (1) HUP0302732A2 (hu)
IL (1) IL156506A0 (hu)
NO (1) NO20033117L (hu)
NZ (1) NZ526676A (hu)
PL (1) PL361879A1 (hu)
RU (1) RU2288739C2 (hu)
WO (1) WO2002064160A2 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109166B1 (en) * 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
MXPA03011554A (es) 2001-06-13 2004-10-28 Magnachem Int Lab Inc Formulaciones de lactona y metodos de uso.
CZ20033123A3 (cs) * 2001-06-25 2004-11-10 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farmaceutické prostředky, které inhibují proliferaci adenomů hypofýzy
AU2003267199A1 (en) * 2002-09-13 2004-04-30 Attenuon, Llc Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent
US20060234922A1 (en) * 2002-10-31 2006-10-19 Yoshiko Takayama Remedy for corneal failure
CN102579427A (zh) 2002-11-05 2012-07-18 马格纳化学国际实验室公司 合成的内酯制剂及其使用方法
WO2005056520A1 (en) * 2003-12-12 2005-06-23 Oy Juvantia Pharma Ltd Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
WO2005102315A1 (en) 2004-04-23 2005-11-03 Magnachem International Laboratories, Inc. Synthetic lactone formulations for pain control
CN1317031C (zh) * 2005-09-14 2007-05-23 上海第二医科大学附属新华医院 增强实体肿瘤细胞化疗敏感性的高效混合制剂
JP2011512215A (ja) 2008-02-21 2011-04-21 エグザカトゥ 活性成分又は薬剤用、特に水溶性のもの用の保護／保持層を備える植込み型医用装置
CN102741336B (zh) 2009-12-01 2014-03-19 株式会社普利司通 改性橡胶组合物和制备方法
FR3052075B1 (fr) 2016-06-01 2022-01-07 Hexacath Dispositif formant catheter d'infusion pour traiter au moins une obstruction partielle ou totale dans un conduit, tel que conduit corporel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
TW334434B (en) * 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
EP0960123A4 (en) * 1996-11-07 2004-05-19 Univ Leland Stanford Junior BRANCHED PROTEIN AND CODING SEQUENCE
US6124256A (en) * 1998-03-27 2000-09-26 Haeyry; Pekka Method for the prevention of a patient's fibroproliferative vasculopathy
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
CA2246791A1 (en) * 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
US6903074B1 (en) * 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US20020103526A1 (en) * 2000-12-15 2002-08-01 Tom Steinke Protective coating for stent

Also Published As

Publication number Publication date
WO2002064160A8 (en) 2003-01-30
NO20033117D0 (no) 2003-07-08
CN1531441A (zh) 2004-09-22
CZ20031695A3 (en) 2004-03-17
US20040082517A1 (en) 2004-04-29
NO20033117L (no) 2003-09-04
CA2433785C (en) 2009-08-04
JP4099065B2 (ja) 2008-06-11
WO2002064160A3 (en) 2004-02-19
AU2002243552C1 (en) 2006-08-31
RU2288739C2 (ru) 2006-12-10
PL361879A1 (en) 2004-10-04
NZ526676A (en) 2005-03-24
EP1409007A2 (en) 2004-04-21
KR20030068585A (ko) 2003-08-21
WO2002064160A2 (en) 2002-08-22
AU2002243552B2 (en) 2005-03-10
JP2004527483A (ja) 2004-09-09
US7084117B2 (en) 2006-08-01
RU2003124748A (ru) 2005-01-10
IL156506A0 (en) 2004-01-04
CA2433785A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
FI974368A (fi) Kasvuhormonin vapautumista edistäviä dipeptidejä
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
DE60233040D1 (de) Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
GB0223040D0 (en) Therapeutic compounds
EP1983000A3 (en) Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
NO20034056D0 (no) Proliferative sykdommer
HUP0302732A2 (hu) Érproliferációt gátló gyógyszerészeti készítmények, és eljárás azok alkalmazására
EP1582210A3 (en) Compositions and methods for treating or preventing surgical adhesions
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
HUP0004271A2 (hu) Elhízás kezelésére szolgáló, amilint vagy amilin-agonistát tartalmazó készítmények
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
YU13301A (sh) Muskarinski agonisti i antagonisti
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees